Q2 2025 Management View Steven O. Vondran, President and CEO, stated that "2025 continues to be a good year." He highlighted ...

Novo Nordisk's stock has dropped 21% after the company lowered its sales forecast and named Mike Doustdar as the new CEO.

Schneider adds that investors seem optimistic about American Tower due to stronger domestic organic growth heading into ...

The upgrade for emerging markets reflects a more optimistic outlook globally by the Fund, which nudged global GDP growth ...

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 ...

"Despite these welcome developments, tariffs remain historically high," the IMF's chief economist said on Tuesday.

Pharma giant Novo Nordisk A/S (NYSE:NVO) is plunging 21% to trade at a nearly three-year low of $54.27, after the company's ...

American Tower (AMT) stock dipped 2.3% in Tuesday premarket trading after REIT's 2025 AFFO guidance midpoint was ...

The IMF on Tuesday raised its global growth forecasts for 2025 and 2026 slightly, citing stronger-than-expected purchases ...

The International Monetary Fund has revised India’s economic growth forecast upwards to 6.4% for both 2025 and 2026, citing a ...

Discover AtriCure's standout Q2 2025 performance with 17% revenue growth, boosted by product innovation and international expansion.

The business has secured projects that include 400 kV quad transmission lines in India, 500/ 400/ 220 kV overhead transmission lines in the overseas market, and the supply of towers, hardware, and pol ...